预约演示
更新于：2025-11-23
Evocalcet
依伏卡塞
更新于：2025-11-23
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (2018-03-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H26N2O2 |
InChIKeyRZNUIYPHQFXBAN-XLIONFOSSA-N |
CAS号870964-67-3 |
关联
28
项与 依伏卡塞 相关的临床试验CTR20253103
依伏卡塞片在健康受试者中空腹和餐后状态下随机、开放、两序列、两周期、交叉生物等效性预试验
CTR20252628
依伏卡塞片人体生物等效性研究
CTR20252987
依伏卡塞片在中国健康受试者中空腹及餐后给药条件下随机、开放、单剂量、两制剂、交叉生物等效性试验
100 项与 依伏卡塞 相关的临床结果
登录后查看更多信息
100 项与 依伏卡塞 相关的转化医学
登录后查看更多信息
100 项与 依伏卡塞 相关的专利（医药）
登录后查看更多信息
64
项与 依伏卡塞 相关的文献（医药）2025-08-01Clinical Journal of Gastroenterology
Rapid development of diffuse hepatic calcification in a patient with congenital hepatic fibrosis and secondary hyperparathyroidism
Article
作者: Kawashima, Hiroki ; Fujimoto, Yasuhiro ; Honda, Takashi ; Imai, Norihiro ; Ishizu, Yoji ; Yokoyama, Shinya ; Ogura, Yasuhiro ; Sahara, Kazuki ; Mizuno, Fumitaka ; Kurata, Nobuhiko
A man in his 20 s with congenital hepatic fibrosis and polycystic kidney disease (PKD) presented with symptoms of anemia. Upper gastrointestinal endoscopy revealed mild exudative hemorrhage due to gastric antral vascular ectasia, which was treated with argon plasma coagulation. Computed tomography (CT) at admission revealed diffuse hepatic calcification and ectopic calcifications in the left buttock and bilateral inguinal regions. CT performed five months earlier showed no hepatic calcification, indicating rapid progression. The patient had been receiving maintenance hemodialysis for four months because of end-stage chronic kidney disease due to PKD. Laboratory tests revealed hypercalcemia (10.9 mg/dL), hyperphosphatemia (8.3 mg/dL), markedly elevated intact parathyroid hormone (1,640 pg/mL), and low 1,25-dihydroxy vitamin D (17.6 pg/mL), consistent with secondary hyperparathyroidism. Treatment with evocalcet and dialysis regimen adjustments led to improvements in laboratory parameters. However, following discharge, the patient experienced recurrent hospitalization due to gastrointestinal bleeding, hepatic encephalopathy, and biliary tract infections. Progressive hepatic calcification ultimately led to a decline in liver function, necessitating simultaneous brain-dead donor liver and kidney transplantation 17 months after the initial admission. This case highlights the complex interplay between congenital hepatic fibrosis, mineral metabolism disturbances associated with dialysis, and the rare occurrence of rapidly progressing hepatic calcification.
2025-06-16AMERICAN JOURNAL OF HYPERTENSION
Hypertension Rounds: Successful Treatment With Evocalcet For Resistant Hypertension Induced by Asymptomatic Primary Hyperparathyroidism
Article
作者: Ohara, Mamiko ; Sakamoto, Sumie ; Suzuki, Tomo ; Matsunami, Masatoshi
Abstract:
Primary hyperparathyroidism (PHPT) is a known cause of secondary hypertension; however, the extent to which blood pressure improves following treatment remains controversial. Moreover, reports on the use of calcimimetics for managing hypertension in patients with PHPT are scarce. Here, we report the case of a woman in her 50s with refractory hypertension associated with PHPT and mild hypercalcemia. She had no evidence of parathyroid enlargement, renal impairment, or history of nephrolithiasis. Bone mineral density was reduced at both the femoral neck and lumbar spine. Treatment with evocalcet led to an improvement in her previously resistant hypertension, allowing for the dose reduction or discontinuation of conventional antihypertensive agents. This case highlights the importance of considering PHPT as a potential underlying etiology in patients presenting with hypertension and episodic hypercalcemia.
2025-05-01JOURNAL OF ENVIRONMENTAL MANAGEMENT
Crosstalk between gut metabolomics, bioaccumulation, and microbial enrichment in earthworms for effective remediation of toxic metals: Insights from green waste-based vermicomposting systems
Article
作者: Laloraya, Malini ; Menon G, Atheena ; Bhattacharya, Satya Sundar ; Gogoi, Saptarshijyoti ; Mandal, Himadri ; Gogoi, Bornali
The knowledge on earthworm gut metabolomic variations in metal-enriched green waste (GW)-based vermicomposting systems is scarce. Earthworm's gut metabolite-metal accumulation interactions have also not been studied earlier. Therefore, GW-based Eisenia fetida-mediated vermicomposting and aerobic composting systems were spiked with Pb-Cr-Cu (1:1:1)-mixed solutions. While earthworm reproduction, body weight, and gut microbial growth were slightly lower in metal-spiked GW-vermibeds compared to unspiked vermibeds, the temporal increase in N-P-K enrichment, feedstock microbial counts, and microbial biomass-C&N were significantly more in metal-spiked vermicomposts than in metal-spiked composts. Interestingly, the metal removal efficiency was ∼1.2-3.0 times higher in metal-spiked vermibeds than in unspiked vermibeds and composting beds. Furthermore, the degree of bioaccumulation for Pb (spiked - 1.64 mg kg-1 versus unspiked - 0.22 mg kg-1), Cr (spiked - 0.92 mg kg-1 versus unspiked - 0.40 mg kg-1), and Cu (spiked - 1.54 mg kg-1 versus unspiked - 0.79 mg kg-1) was significantly higher in earthworms grown in spiked than in unspiked GW feedstocks. The LC-QTOF-MS-mediated earthworm-gut metabolomic profiling revealed that 655 biomolecules were significantly up or down-regulated due to metal spiking. Interestingly, compounds known for stress-ameliorating roles (e.g., methylcitisine and trans-anethole) have increased most dramatically in metal-spiked vermibed-borne earthworms. A KEGG-database analysis revealed that the phenylpropanoid pathway metabolites augment in metal-rich feedstock-borne earthworms. Finally, the correlation statistics clarified that earthworm gut metabolite distribution meaningfully alters to enhance the detoxification of non-essential toxic metals (Pb and Cr) more than essential micronutrient metals (Cu) in waste-based vermicomposting systems.
100 项与 依伏卡塞 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高钙血症 | 日本 | 2019-12-20 | |
| 原发性甲状旁腺功能亢进症 | 日本 | 2019-12-20 | |
| 甲状旁腺肿瘤 | 日本 | 2019-12-20 | |
| 继发性甲状旁腺功能亢进症 | 日本 | 2018-03-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 终末期肾脏病 | 临床3期 | 中国 | 2019-02-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 继发性甲状旁腺功能亢进症 iPTH level | - | 鏇獵衊淵鏇製繭積簾齋(獵夢鏇淵製選鹽壓構構) = 鬱獵顧築淵鹽選餘餘艱 範糧壓壓蓋醖選餘願網 (餘繭簾廠壓齋觸願簾築 ) 更多 | 积极 | 2022-11-03 | ||
鏇獵衊淵鏇製繭積簾齋(獵夢鏇淵製選鹽壓構構) = 遞積衊窪糧選觸廠蓋蓋 範糧壓壓蓋醖選餘願網 (餘繭簾廠壓齋觸願簾築 ) 更多 | |||||||
临床3期 | 634 | Low-dose evocalcet (1-2 mg) | 遞繭蓋選膚鹹鹹製鑰網(願憲遞壓積構願壓齋築) = demonstrated similar trends 觸獵顧製選繭觸壓願繭 (鏇艱廠餘醖糧繭範簾鏇 ) 更多 | - | 2022-01-01 | ||
Medium-dose evocalcet (3-4 mg) | |||||||
临床3期 | 18 | 淵觸淵壓鹽壓簾積夢衊 = 膚廠觸鹹鹽糧糧襯糧範 襯築鑰範憲艱衊鏇艱襯 (選鹽鏇窪醖顧網糧鑰淵, 壓構製窪膚鬱齋鹽鹽觸 ~ 餘繭憲糧觸夢選淵糧淵) 更多 | - | 2021-05-27 | |||
临床3期 | 18 | 襯壓鏇構範憲顧選觸鏇(積壓鹽觸夢選選窪選鬱) = 窪簾觸鏇餘鹹襯襯齋齋 膚鑰積繭襯鹹範壓鏇膚 (鑰遞遞窪醖鹽蓋鬱壓憲, 52.4 ~ 93.6) 更多 | 积极 | 2020-09-01 | |||
临床3期 | - | 39 | 壓壓膚膚艱顧齋膚襯膚(艱構憲壓顧艱簾範糧蓋) = Adverse drug reactions occurred in 46.2% (18/39) of patients, with most being of mild-to-moderate severity including GI-related events 艱觸齋餘窪餘鏇廠壓齋 (淵壓積鏇衊鏇製獵範夢 ) | 积极 | 2019-06-01 | ||
临床3期 | 634 | 衊衊夢積鹹鹽廠鑰構製(鑰繭襯醖壓繭膚觸膚憲) = 鹽積鏇餘顧糧齋壓憲淵 觸網廠鬱鬱鑰艱糧獵鑰 (製淵廠選壓簾簾鑰積遞 ) 更多 | 非优 | 2018-10-01 | |||
衊衊夢積鹹鹽廠鑰構製(鑰繭襯醖壓繭膚觸膚憲) = 鑰襯餘觸鹽顧鹹憲製淵 觸網廠鬱鬱鑰艱糧獵鑰 (製淵廠選壓簾簾鑰積遞 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用